CEO Files Intent to Sell Over $5 Million in Company Stock
PTGX has more than doubled off its 52-week low of $39.6.
Summary
Protagonist Therapeutics' CEO filed a Form 144 to sell $5.39 million in stock, continuing a pattern of insider sales.
Key Events · Ownership and Investor Activity · PTGX
-
CEO Files Intent to Sell Shares
Dinesh Patel, CEO of Protagonist Therapeutics, filed a Form 144 to sell 54,700 shares of common stock.
-
Significant Proposed Transaction Value
The proposed sale is valued at approximately $5.39 million.
-
Follows Recent Insider Sales
This intent to sell follows previous sales by the CEO totaling $4.06 million in the past three months, contributing to a net insider distribution of nearly $13 million over 90 days.
-
Part of Ongoing Insider Distribution
This filing is part of an ongoing pattern of insider sales, with 10 similar filings from various insiders in the last 90 days.
Analysis · PTGX · Life Sciences
Protagonist Therapeutics' CEO, Dinesh Patel, has filed a Form 144 indicating an intent to sell 54,700 shares of common stock, valued at approximately $5.39 million. This proposed sale follows previous sales by the CEO totaling over $4 million in the past three months, contributing to a broader pattern of insider distribution. While the percentage of market cap is small, the absolute dollar value and the CEO's role make this a notable event, signaling a continued reduction in executive holdings.
At the time of this filing, PTGX was trading at $100.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4B. The 52-week trading range was $39.60 to $105.69. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.